List of Excipients in Branded Drug OXYGEN/HELIUM 20/80

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
MATHESON TRI-GAS INC	OXYGEN/HELIUM 20/80	oxygen/helium 20/80	55037-600	HELIUM
MATHESON TRI-GAS INC	OXYGEN/HELIUM 20/80	oxygen/helium 20/80	55037-602	HELIUM

Oxygen/Helium 20/80 Excipient Strategy and Commercial Opportunities

Last updated: October 26, 2026

Oxygen/helium 20/80 is better analyzed as a medical-gas combination than as a conventional pharmaceutical drug. Helium is the dominant component, while oxygen supports patient breathing. The mixture has no traditional excipient. Its commercial value depends on gas purity, validated blending, cylinder and valve systems, delivery-device compatibility, clinical positioning, and regulatory classification.

The most credible opportunity is controlled respiratory support where low gas density can improve flow through narrowed airways or reduce turbulent resistance. The principal commercial constraint is the 20% oxygen concentration. Because this is close to, but slightly below, ambient oxygen concentration, the product cannot be treated as an oxygen-enrichment therapy and requires careful clinical-use controls.

What is Oxygen/Helium 20/80 used for?

Oxygen/helium 20/80, also called heliox 20/80 when expressed as oxygen/helium, is an inhaled medical-gas mixture containing approximately 20% oxygen and 80% helium by volume.

Helium has substantially lower density than nitrogen-containing air. Replacing nitrogen with helium can reduce gas density and lower resistance to flow through partially obstructed airways. Potential clinical applications include:

Application	Commercial rationale	Evidence and risk profile
Upper-airway obstruction	May improve airflow through narrowed passages	Potentially useful as an adjunct, not a substitute for definitive airway management
Croup and post-extubation stridor	May reduce work of breathing in selected patients	Clinical evidence is mixed and generally supports adjunctive use
Severe asthma or obstructive exacerbations	May reduce turbulent flow and work of breathing	Benefit is inconsistent; oxygenation must be monitored
Noninvasive ventilation	Can be delivered through selected ventilator systems	Requires equipment validation because helium changes flow measurement and performance
Aerosol drug delivery	Low-density gas can affect aerosol transport	Requires product-specific studies for nebulizers and inhalation systems
Pulmonary-function testing	Can be used in specialized measurement systems	Smaller, technical-market opportunity
Emergency transport	Portable cylinders can provide an adjunct for airway obstruction	Logistics, cylinder weight, and device compatibility determine feasibility

The product should not be positioned as a general oxygen therapy. At 20% oxygen, the mixture has little oxygen-enrichment capacity. Its primary functional attribute is helium-driven reduction in gas density.

Is Oxygen/Helium 20/80 a drug or a medical gas?

Under U.S. law, medical gases are regulated as drugs when intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. FDA has established a medical-gas framework covering products such as oxygen, nitrogen, nitrous oxide, carbon dioxide, and helium, including manufacturing, labeling, and registration requirements.[1]

The regulatory classification depends on the product’s labeling, manufacturing controls, intended use, and marketing pathway. A manufacturer selling a defined oxygen/helium mixture for inhalation must establish:

• Identity and concentration of each component.
• Impurity limits.
• Batch or fill uniformity.
• Stability during storage and transport.
• Cylinder and closure compatibility.
• Microbiological and particulate controls where applicable.
• Labeling that identifies the gas composition and clinical use.
• Delivery-device compatibility.
• Procedures for recalls, complaints, and adverse events.

The product is unlikely to fit the conventional pharmaceutical model in which excipients improve solubility, stability, taste, or absorption. Helium and oxygen are the therapeutic components. The container-closure system is the primary product-enabling technology.

What excipients can be used in Oxygen/Helium 20/80?

Traditional excipients are generally inappropriate for a compressed-gas inhalation product. Oils, lubricants, propellants, stabilizers, preservatives, and particulate additives can create toxicity, flammability, contamination, or device-performance risks.

The relevant “excipient strategy” is therefore a materials and delivery-system strategy.

Product element	Function	Key development requirement
Oxygen	Supports respiration	Assay, purity, moisture and contaminant controls
Helium	Reduces gas density	Assay, purity, pressure control and leak testing
Cylinder alloy	Stores compressed mixture	Compatibility, pressure rating, corrosion resistance
Internal cylinder coating	Limits contamination or interaction	Extractables, leachables and aging assessment
Valve and regulator	Controls delivery	Flow accuracy across pressure and temperature ranges
Gaskets and seals	Maintain integrity	Helium permeation and material compatibility testing
Tubing and masks	Deliver gas to patient	Low leakage, low adsorption and validated flow performance
Humidification components	Manage airway comfort	Must not materially alter composition or flow
Label and color coding	Prevent medication errors	Clear composition and oxygen-warning statements

Helium is a small molecule with high diffusivity. Leakage control is therefore more important than for many conventional medical gases. Seals, valve seats, tubing, and regulator materials require specific helium-permeation and pressure-decay testing.

A manufacturer should avoid materials that contain hydrocarbon lubricants or residues incompatible with oxygen service. Although the oxygen level is only 20%, oxygen-service cleanliness remains relevant because compressed-gas systems can contain higher local oxygen concentrations during filling, segregation, or servicing.

What formulations are protected by Oxygen/Helium 20/80?

The formulation itself is difficult to protect broadly. A claim covering only “20% oxygen and 80% helium” may face prior-art and obviousness challenges because oxygen-helium mixtures, including heliox mixtures, have long been used in respiratory medicine.

More defensible protection may focus on:

1. Narrow concentration ranges linked to a defined clinical outcome.
2. A gas mixture combined with a specific ventilator or nebulizer.
3. A validated delivery protocol for a defined patient population.
4. Pressure, flow, humidity, or temperature parameters.
5. A cylinder-valve-regulator assembly that preserves composition.
6. Methods for preventing helium leakage or concentration drift.
7. Aerosol formulations delivered through the mixture.
8. Closed-loop oxygen monitoring and automated blending.
9. Manufacturing processes that achieve concentration uniformity.
10. Disposable delivery kits configured for the mixture.

The strongest patent claims are likely to sit around delivery hardware, monitoring software, and integrated respiratory systems rather than the gas composition alone.

How strong is the patent estate for Oxygen/Helium 20/80?

The composition-level patent estate is likely weak because the underlying concept is established. Commercial protection is more likely to arise from device integration, manufacturing controls, and use-specific claims.

IP category	Expected protection strength	Commercial relevance
Oxygen/helium composition alone	Low	Broad claims face prior-art risk
Defined concentration range	Low to moderate	Stronger if tied to unexpected clinical performance
Respiratory-use method	Moderate	Depends on patient selection and clinical evidence
Nebulizer or ventilator integration	Moderate to strong	Can create switching costs and device lock-in
Cylinder and valve architecture	Moderate	Protects operational reliability
Automated blending and monitoring	Stronger	Useful for hospitals and critical-care systems
Manufacturing and fill process	Moderate	Can protect quality and reduce batch failure
Trade secrets	Moderate	Especially useful for filling, QA and logistics

No product-specific patent number, assignee, filing date, or expiration date can be reliably assigned to “OXYGEN/HELIUM 20/80” without a defined sponsor, product code, or jurisdiction. The mixture name alone does not identify a single proprietary product.

What is the FDA regulatory status and Orange Book status?

The FDA regulatory status cannot be inferred from the mixture name alone. Oxygen and helium may be handled under medical-gas requirements, but a specific commercial product can have a different status depending on its sponsor, labeling, application, and intended use.

The Orange Book is not a complete source for every medical-gas product. A product may be regulated without having the type of Orange Book listing commonly associated with oral tablets, injectable drugs, or inhaled small-molecule products approved under an NDA. Regulatory review may instead involve medical-gas registration, drug establishment registration, product listing, or another FDA pathway determined by the product’s intended use and manufacturing configuration.[1]

For commercial diligence, the relevant regulatory questions are:

• Is the product listed as a finished medical gas?
• Is it manufactured under an approved application or another recognized FDA pathway?
• Is the mixture labeled for direct inhalation?
• Does the label identify a prescription-only use?
• Are the cylinders and delivery systems cleared, approved, or otherwise authorized?
• Does the sponsor have compliant current good manufacturing practice controls?
• Are there restrictions on hospital compounding or point-of-use blending?

When does Oxygen/Helium 20/80 lose exclusivity?

There is no universal exclusivity date for Oxygen/Helium 20/80. Loss of exclusivity depends on the sponsor’s patents, regulatory exclusivity, device claims, trade secrets, and market access arrangements.

For a conventional drug product, exclusivity could arise from:

• Patent term, generally measured from the relevant nonprovisional filing date.
• FDA statutory exclusivity.
• Orphan-drug exclusivity, if applicable.
• Pediatric exclusivity, if granted.
• Device or software protection.
• Contractual hospital or distributor arrangements.

For a medical-gas mixture, the practical entry barrier may end before any formal patent expiration. A competing manufacturer may be able to market a clinically equivalent mixture if it can meet regulatory, quality, packaging, and distribution requirements.

Are Paragraph IV challenges relevant?

Paragraph IV litigation is relevant only if the product is listed in the Orange Book with patents that an abbreviated new drug application applicant must address. A standalone medical-gas mixture may not create the same Paragraph IV pathway as a conventional NDA-approved drug.

Potential generic or competing-product routes include:

• A product application addressing the same therapeutic gas.
• A drug-master-file-supported commercial product.
• A separately manufactured medical gas with equivalent composition.
• Hospital or institutional supply arrangements.
• Device-linked products that use the same gas but a different delivery system.

If no Orange Book-listed product-specific patents exist, Paragraph IV litigation may not be the main competitive mechanism. Market entry would instead turn on regulatory compliance, supply reliability, hospital purchasing, and clinical adoption.

What patent litigation affects Oxygen/Helium 20/80?

No litigation can be attributed to the product name without identifying a sponsor or branded product. The most plausible litigation categories are:

• Patent disputes over heliox delivery devices.
• Claims involving ventilator calibration or gas-flow measurement.
• Aerosol-delivery systems using helium-containing mixtures.
• Cylinder valves, regulators, and leak-control technologies.
• Hospital procurement or distribution contracts.
• Product-liability claims involving incorrect oxygen concentration or device incompatibility.

A gas manufacturer with no proprietary delivery platform is more exposed to price competition. A manufacturer that controls a validated device-gas combination may have stronger enforcement leverage.

What manufacturing and IP barriers affect commercial entry?

The main barriers are operational rather than formulation-based.

Gas blending and fill control

The manufacturer must demonstrate concentration accuracy across cylinders, fill lots, pressure states, and storage periods. Helium and oxygen can behave differently during compression, temperature changes, and leakage events. A validated fill-and-test process is commercially important.

Cylinder logistics

Medical-gas distribution requires cylinder inspection, tracking, cleaning, filling, testing, and return logistics. Helium supply can be exposed to upstream scarcity and price volatility. A reliable supply agreement may be more valuable than a narrow composition patent.

Equipment compatibility

Heliox can affect ventilator flow sensors, turbine performance, trigger sensitivity, delivered-volume calculations, and alarm thresholds. A product sold without validated equipment guidance may face hospital adoption barriers.

Clinical workflow

Hospitals may need protocols for patient selection, oxygen monitoring, respiratory-therapy administration, and transition to conventional oxygen or ventilation. Products bundled with protocols and training can command higher margins than commodity cylinders.

What commercial opportunities exist?

The strongest opportunities are in integrated hospital solutions rather than raw gas sales.

Opportunity	Revenue model	Strategic attractiveness
Hospital cylinder supply	Per-cylinder or contract pricing	Moderate; vulnerable to commodity competition
Emergency-department heliox kits	Gas plus mask, regulator and protocol	High
Pediatric respiratory packages	Recurring supply and disposable interfaces	Moderate to high
Ventilator-compatible systems	Gas, hardware and software	High
Nebulizer-compatible delivery	Gas plus drug-delivery platform	High if clinical benefit is demonstrated
Home-care applications	Rental, refill and support services	Low to moderate due to safety and logistics
Clinical trial supply	Custom fill and documentation	Moderate
International distributor licensing	Territory-based supply agreements	Moderate
Automated gas-blending systems	Hardware, software and service contracts	High

A 20/80 mixture may have a specific niche where the primary objective is low-density gas flow and the patient does not require oxygen enrichment. In patients with substantial oxygen need, higher-oxygen heliox mixtures or conventional oxygen therapy may be more appropriate. Product positioning must therefore distinguish airway-flow support from oxygen supplementation.

How does Oxygen/Helium 20/80 compare with other heliox mixtures?

Mixture	Main characteristic	Likely positioning
20% oxygen / 80% helium	Maximum helium fraction among common heliox concepts; oxygen near ambient concentration	Airway-flow support where oxygenation is adequate
21% oxygen / 79% helium	Similar to ambient oxygen concentration	General heliox reference mixture
30% oxygen / 70% helium	More oxygen support, somewhat higher gas density	Patients needing greater oxygen availability
40% oxygen / 60% helium	Higher oxygen fraction, reduced helium effect	More oxygen-dependent patients
Oxygen-enriched heliox	Oxygen concentration above ambient	Respiratory support with concurrent hypoxemia

The commercial tradeoff is direct: increasing helium concentration may preserve the low-density advantage, while increasing oxygen concentration broadens use in hypoxemic patients but reduces the relative helium benefit.

What generic launch risks exist?

A competing manufacturer could potentially enter with a compositionally equivalent gas if it satisfies regulatory and quality requirements. Entry risk is highest when:

• The composition is unpatented or protected only by expired claims.
• The sponsor lacks Orange Book-listed patents.
• Cylinders and regulators are standard industry components.
• Hospitals purchase gas through competitive tenders.
• Clinical differentiation is weak.
• Helium supply is available through multiple distributors.

Entry risk is lower when the incumbent controls:

• A validated gas-delivery platform.
• Hospital protocols and respiratory-therapy training.
• Integrated monitoring software.
• Exclusive distribution arrangements.
• Strong clinical evidence in a defined indication.
• Reliable helium sourcing and national cylinder logistics.

What licensing deals could create value?

Potential licensing targets include:

• Ventilator manufacturers seeking a validated heliox operating mode.
• Nebulizer companies developing low-density aerosol delivery.
• Hospital-gas distributors with regional cylinder networks.
• Respiratory-monitoring companies offering automated oxygen control.
• Pediatric and emergency-care suppliers.
• Manufacturers of disposable masks, circuits, and regulators.

The most valuable deal structure would likely combine gas supply, device compatibility, clinical protocols, and territory-based distribution. A license limited to the gas composition would have weaker defensibility unless it includes manufacturing know-how or regulatory support.

Key Takeaways

• Oxygen/Helium 20/80 is a medical-gas combination, not a conventional excipient-containing pharmaceutical.
• Helium and oxygen are the functional components; the commercial excipient strategy centers on cylinders, valves, seals, regulators, tubing, and delivery interfaces.
• Composition-level patent protection is likely limited because heliox mixtures are established technologies.
• Stronger IP opportunities involve ventilator integration, aerosol delivery, automated monitoring, leak prevention, and validated manufacturing.
• The FDA status and Orange Book position depend on the specific sponsor, label, application, and jurisdiction.
• Paragraph IV litigation may be irrelevant if no Orange Book-listed product-specific patents exist.
• Commercial value is highest in integrated hospital respiratory systems, emergency-care kits, and device-linked delivery platforms.
• The central clinical and commercial constraint is the 20% oxygen concentration, which limits use in patients requiring oxygen enrichment.

FAQs

Is Oxygen/Helium 20/80 the same as heliox?

Yes. When expressed as oxygen/helium, 20/80 is a heliox mixture containing approximately 20% oxygen and 80% helium.

Can Oxygen/Helium 20/80 be used as a substitute for medical oxygen?

No. Its oxygen concentration is near ambient air and is not designed to provide substantial oxygen enrichment.

Does Oxygen/Helium 20/80 require a conventional pharmaceutical excipient?

No. The mixture generally does not require a conventional excipient. Product performance depends on gas purity, container materials, valves, regulators, delivery circuits, and monitoring.

Is heliox 20/80 patentable?

A broad claim to the gas composition is likely difficult to defend. More viable protection may cover a defined clinical use, delivery device, monitoring system, manufacturing process, or integrated gas-and-device platform.

Can a generic manufacturer sell an equivalent Oxygen/Helium 20/80 product?

Potentially, subject to applicable FDA requirements, quality standards, labeling controls, manufacturing authorization, cylinder compliance, and any enforceable patents or contracts held by the incumbent.

References

1. U.S. Food and Drug Administration. (2017). Medical gas rule: Current good manufacturing practice, certification, postmarketing safety reporting, and labeling requirements. Federal Register, 82 Fed. Reg. 5428.

2. U.S. Food and Drug Administration. (2024). Medical gases. FDA.

3. American Association for Respiratory Care. (2005). AARC clinical practice guideline: Use of helium-oxygen mixtures in the treatment of patients with airway obstruction. Respiratory Care, 50(9), 1219-1227.

4. Global Initiative for Asthma. (2024). Global strategy for asthma management and prevention. GINA.

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.